GlassScriptPhysician profile
Robert A Mileski
NPI 1659451946
$15,592.68
in general payments reported to CMS, 2019-2025
31 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,597 · 2020: $1,383 · 2021: $2,080 · 2022: $1,843 · 2023: $655 · 2024: $204 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $7,571.13 | 2019 | |
| Stryker Corporation | $1,774.82 | 2019-2025 | Blueprint Patient Specific Instrumentation, T2, Variax |
| Arthrex, INC. | $1,427.84 | 2021 | |
| Goode Surgical INC | $1,360.62 | 2020 | |
| Impactortho, INC. | $995.41 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $496.10 | 2019-2025 | Comprehensive Shoulder System, Persona |
| Smith+Nephew, INC. | $401.38 | 2019-2024 | Real Intelligence |
| Amgen INC. | $322.62 | 2021-2023 | Enbrel, Tavneos, Otezla |
| Arthrosurface Incorporated | $182.58 | 2019 | |
| Catalyst Orthoscience | $167.61 | 2019 | |
| Linvatec Corporation | $147.78 | 2022 | |
| Janssen Biotech, INC. | $141.95 | 2021-2023 | Tremfya |
| Depuy Synthes Sales INC. | $111.23 | 2025 | Actis |
| Orthofix Medical, INC. | $100.75 | 2019-2024 | Accelstim, Physio-Stim |
| Lilly USA, LLC | $50.45 | 2022-2023 | Taltz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $43.39 | 2021-2023 | Genvisc 850 Sodium Hyaluronate |
| Novartis Pharmaceuticals Corporation | $32.17 | 2022-2023 | |
| Mylan Institutional INC. | $27.46 | 2023 | Hulio |
| Abbott Laboratories | $24.29 | 2024 | Proclaim |
| Ethicon US, LLC | $22.97 | 2019 | |
| Djo, LLC | $21.55 | 2023 | Cmf |
| Moximed, INC | $20.99 | 2025 | Misha Knee System, Small, Left |
| Trice Medical, INC. | $19.44 | 2024 | |
| Illuminoss Medical, INC. | $18.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.10 | 2022 | |
| Vericel Corporation | $17.17 | 2024 | Maci |
| Fidia Pharma USA INC. | $16.20 | 2025 | Hymovis |
| Pacira Pharmaceuticals Incorporated | $15.91 | 2019 | |
| Innovation Technologies INC | $15.43 | 2025 | Irrisept |
| Dynasplint Systems INC. | $14.47 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mileski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.